169 related articles for article (PubMed ID: 33050940)
21. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.
Hurvitz N; Dinur T; Becker-Cohen M; Cozma C; Hovakimyan M; Oppermann S; Demuth L; Rolfs A; Abramov A; Zimran A; Revel-Vilk S
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234327
[TBL] [Abstract][Full Text] [Related]
22. Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme replacement therapy.
Weinreb NJ; Lee RE
Crit Rev Oncog; 2013; 18(3):177-95. PubMed ID: 23510063
[TBL] [Abstract][Full Text] [Related]
23. Correlating liver stiffness with disease severity scoring system (DS3) values in Gaucher disease type 1 (GD1) patients.
Serai SD; Naidu AP; Andrew Burrow T; Prada CE; Xanthakos S; Towbin AJ
Mol Genet Metab; 2018 Mar; 123(3):357-363. PubMed ID: 29361370
[TBL] [Abstract][Full Text] [Related]
24. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
Hollak CE; Hughes D; van Schaik IN; Schwierin B; Bembi B
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
[TBL] [Abstract][Full Text] [Related]
25. A validated disease severity scoring system for adults with type 1 Gaucher disease.
Weinreb NJ; Cappellini MD; Cox TM; Giannini EH; Grabowski GA; Hwu WL; Mankin H; Martins AM; Sawyer C; vom Dahl S; Yeh MS; Zimran A
Genet Med; 2010 Jan; 12(1):44-51. PubMed ID: 20027115
[TBL] [Abstract][Full Text] [Related]
26. The role of high density lipoprotein in Type 1 Gaucher disease.
Watad S; Abu-Saleh N; Yousif A; Agbaria A; Rosenbaum H
Blood Cells Mol Dis; 2018 Feb; 68():43-46. PubMed ID: 27876360
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3).
Weinreb NJ; Finegold DN; Feingold E; Zeng Z; Rosenbloom BE; Shankar SP; Amato D
Orphanet J Rare Dis; 2015 May; 10():64. PubMed ID: 25994334
[TBL] [Abstract][Full Text] [Related]
28. Polyneuropathy in Gaucher disease type 1 and 3 - a descriptive case series.
Andréasson M; Solders G; Björkvall CK; Machaczka M; Svenningsson P
Sci Rep; 2019 Oct; 9(1):15358. PubMed ID: 31653957
[TBL] [Abstract][Full Text] [Related]
29. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.
Sidhu K; Boyd SK; Khan A
Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532
[TBL] [Abstract][Full Text] [Related]
30. Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients.
Machaczka M; Paucar M; Björkvall CK; Smith NJC; Cox TM; Forsgren L; Svenningsson P
Blood Cells Mol Dis; 2018 Feb; 68():86-92. PubMed ID: 27789132
[TBL] [Abstract][Full Text] [Related]
31. Atypical cytomorphology of Gaucher cells is frequently seen in bone marrow smears from untreated patients with Gaucher disease type 1.
Markuszewska-Kuczynska A; Klimkowska M; Regenthal S; Bulanda A; Kämpe Björkvall C; Machaczka M
Folia Histochem Cytobiol; 2015; 53(1):62-9. PubMed ID: 25736845
[TBL] [Abstract][Full Text] [Related]
32. Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease.
Sahasrabudhe SA; Terluk MR; Rudser KD; Cloyd JC; Kartha RV
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012454
[TBL] [Abstract][Full Text] [Related]
33. Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment.
Regenboog M; Bohte AE; Akkerman EM; Stoker J; Hollak CEM
Br J Haematol; 2017 Nov; 179(4):635-647. PubMed ID: 28905365
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility of different bone marrow examination methods in the diagnosis of adults with sporadic Gaucher disease type 1.
Machaczka M; Markuszewska-Kuczyńska A; Regenthal S; Jurczyszyn A; Gałązka K; Wahlin BE; Klimkowska M
Pol Arch Med Wewn; 2014; 124(11):587-92. PubMed ID: 25188399
[TBL] [Abstract][Full Text] [Related]
35. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
36. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
37. The modulation of inflammatory parameters, Brain-derived neurotrophic factor levels and global histone H4 acetylation status in peripheral blood of patients with Gaucher disease type 1.
de Mello AS; da Silva IR; Reinaldo GP; Dorneles GP; Cé J; Lago PD; Peres A; Elsner VR; Coelho JC
Clin Biochem; 2017 Mar; 50(4-5):228-233. PubMed ID: 27865783
[TBL] [Abstract][Full Text] [Related]
38. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
Zimran A; Wang N; Ogg C; Crombez E; Cohn GM; Elstein D
Am J Hematol; 2015 Jul; 90(7):577-83. PubMed ID: 25903392
[TBL] [Abstract][Full Text] [Related]
39. Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1.
Lorenz F; Pawłowicz E; Klimkowska M; Beshara S; Bulanda Brustad A; Skotnicki AB; Wahlin A; Machaczka M
Blood Cells Mol Dis; 2018 Feb; 68():35-42. PubMed ID: 27816428
[TBL] [Abstract][Full Text] [Related]
40. Comorbidities and pharmacotherapies in patients with Gaucher disease type 1: The potential for drug-drug interactions.
Utz J; Whitley CB; van Giersbergen PL; Kolb SA
Mol Genet Metab; 2016 Feb; 117(2):172-8. PubMed ID: 26674302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
